Moderna (MRNA) Stock Price, News & Analysis

+0.69 (+0.64%)
(As of 03:27 PM ET)
Today's Range
50-Day Range
52-Week Range
2.61 million shs
Average Volume
4.11 million shs
Market Capitalization
$41.57 billion
P/E Ratio
Dividend Yield
Price Target

Moderna MarketRank™ Stock Analysis

Analyst Rating
2.24 Rating Score
18.1% Upside
$126.49 Price Target
Short Interest
6.37% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.28mentions of Moderna in the last 14 days
Based on 26 Articles This Week
Insider Trading
Selling Shares
$11.53 M Sold Last Quarter
Proj. Earnings Growth
From ($7.51) to ($5.50) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.07 out of 5 stars

Medical Sector

182nd out of 909 stocks

Biological Products, Except Diagnostic Industry

20th out of 156 stocks

MRNA stock logo

About Moderna Stock (NASDAQ:MRNA)

Moderna Inc., founded in 2010, is a biotechnology company focused on creating transformative medicines to combat viruses and other diseases. The company utilizes messenger ribonucleic acid (mRNA) technology, which transports information from a living creature's DNA to other parts of the body. The company has experienced rapid growth due to its innovative mRNA technologies, especially as the U.S. authorized the COVID-19 vaccine developed by Moderna Inc. for human use in December 2020.

Moderna Inc. operates in multiple therapeutic areas, including infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases. Its product pipeline includes prophylactic vaccines, localized regenerative therapeutics, cancer vaccines, systemic secreted therapeutics, intratumoral immuno-oncology and systemic intracellular therapeutics. The company is also developing vaccines and therapeutics for other infectious diseases, such as influenza, hMPV+PIV3, respiratory syncytial virus, endemic HCoV, cytomegalovirus, human immunodeficiency virus, herpes simplex virus, Epstein-Barr virus and varicella-zoster virus.

Moderna Inc. is actively working to develop a range of pharmaceutical solutions and vaccines and to increase its strategic alliances. The company has seen success in its innovative mRNA technologies, and its growing partnerships have given them an edge over its competitors. 

As the company continues to advance its technologies and expand its strategic alliances, Moderna Inc. is proving to be a reliable source of transformative medicines to combat viruses and other diseases.

Moderna Inc. has formed strategic partnerships with a variety of pharmaceutical companies, including AstraZeneca PLC, Merck & Co. Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics Inc., Metagenomi Inc., the Defense Advanced Research Projects Agency, Biomedical Advanced Research and Development Authority, Institute for Life Changing Medicines and the Bill & Melinda Gates Foundation. Furthermore, the company has a collaboration and license agreement with Chiesi Farmaceutici S.P.A. 

MRNA Stock Price History

MRNA Stock News Headlines

This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Thousands of investors use this no cost solution | Do you?
In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.
Moderna, Inc. (MRNA)
See More Headlines
Receive MRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Moderna and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Confirmed)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
17 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$6.85 billion
Book Value
$36.33 per share


Free Float
Market Cap
$41.57 billion

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Should I Buy Moderna Stock? MRNA Pros and Cons Explained


Here are some ways that investors could benefit from investing in Moderna, Inc.:

  • Moderna, Inc. is a leading biotechnology company that focuses on developing messenger RNA therapeutics and vaccines for various diseases, including COVID-19.
  • The company has a diverse pipeline of products targeting infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases, providing potential for revenue growth.
  • Moderna has established strategic alliances and collaborations with prominent organizations like AstraZeneca, Merck & Co., Inc., and The Bill & Melinda Gates Foundation, enhancing its research capabilities and market reach.
  • The successful development and commercialization of vaccines like spikevax for COVID-19 demonstrate Moderna's innovation and potential for addressing global health challenges.
  • Recent positive news and advancements in Moderna's research and development activities have the potential to drive stock price growth, offering investors a chance for capital appreciation.


Investors should be bearish about investing in Moderna, Inc. for these reasons:

  • Biotechnology investments can be volatile due to regulatory uncertainties, clinical trial outcomes, and competition, which may pose risks to investor returns.
  • The biopharmaceutical industry is highly competitive, with other companies also focusing on mRNA therapeutics and vaccines, potentially impacting Moderna's market share and profitability.
  • Market fluctuations and investor sentiment towards healthcare and biotechnology sectors can influence Moderna's stock price, leading to short-term price volatility.
  • Investing in biotech companies like Moderna requires a high tolerance for risk, as the industry is subject to scientific, regulatory, and market-related challenges that can affect financial performance.
  • Understanding terms like revenue growth, market reach, and capital appreciation is crucial for investors to assess the financial health and growth potential of Moderna, Inc. before making investment decisions.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, April 12, 2024. Please send any questions or comments about these Moderna pros and cons to

MRNA Stock Analysis - Frequently Asked Questions

Should I buy or sell Moderna stock right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last year. There are currently 2 sell ratings, 9 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MRNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNA, but not buy additional shares or sell existing shares.
View MRNA analyst ratings
or view top-rated stocks.

What is Moderna's stock price target for 2024?

17 equities research analysts have issued 1 year target prices for Moderna's stock. Their MRNA share price targets range from $60.00 to $231.00. On average, they expect the company's share price to reach $126.49 in the next twelve months. This suggests a possible upside of 18.1% from the stock's current price.
View analysts price targets for MRNA
or view top-rated stocks among Wall Street analysts.

How have MRNA shares performed in 2024?

Moderna's stock was trading at $99.45 at the start of the year. Since then, MRNA stock has increased by 7.7% and is now trading at $107.14.
View the best growth stocks for 2024 here

When is Moderna's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our MRNA earnings forecast

How can I listen to Moderna's earnings call?

Moderna will be holding an earnings conference call on Thursday, May 2nd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Moderna's earnings last quarter?

Moderna, Inc. (NASDAQ:MRNA) announced its earnings results on Thursday, February, 22nd. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of ($0.78) by $1.33. The firm earned $2.80 billion during the quarter, compared to analysts' expectations of $2.53 billion. Moderna had a negative trailing twelve-month return on equity of 10.23% and a negative net margin of 68.84%. The company's quarterly revenue was down 44.9% on a year-over-year basis. During the same period in the previous year, the business earned $3.61 EPS.

What guidance has Moderna issued on next quarter's earnings?

Moderna issued an update on its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $4.0 billion-$4.0 billion, compared to the consensus revenue estimate of $4.5 billion.

What is Stéphane Bancel's approval rating as Moderna's CEO?

57 employees have rated Moderna Chief Executive Officer Stéphane Bancel on Stéphane Bancel has an approval rating of 92% among the company's employees. This puts Stéphane Bancel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Moderna own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Moderna investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Johnson & Johnson (JNJ), Alibaba Group (BABA) and Zoom Video Communications (ZM).

When did Moderna IPO?

Moderna (MRNA) raised $499 million in an IPO on Friday, December 7th 2018. The company issued 21,700,000 shares at a price of $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.

Who are Moderna's major shareholders?

Moderna's stock is owned by a number of institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (0.40%), Douglas Lane & Associates LLC (0.10%), Raymond James & Associates (0.04%), Quattro Financial Advisors LLC (0.02%), Amalgamated Bank (0.02%) and Raymond James Financial Services Advisors Inc. (0.02%). Insiders that own company stock include Arpa Garay, David W Meline, Dustin A Moskovitz, James M Mock, Juan Andres, Lori M Henderson, Lori M Henderson, Mark D Mclaughlin, Noubar Afeyan, Paul Sagan, Shannon Thyme Klinger, Stephane Bancel, Stephen Hoge, Tal Zvi Zaks and W Don Cornwell.
View institutional ownership trends

How do I buy shares of Moderna?

Shares of MRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MRNA) was last updated on 4/24/2024 by Staff

From Our Partners